These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 26790556)

  • 1. Unusual pulmonary toxicity of ipilimumab treated by macrolides.
    Mailleux M; Cornélis F; Colin GC; Baurain JF
    Acta Clin Belg; 2015 Dec; 70(6):442-4. PubMed ID: 26790556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma.
    Barjaktarevic IZ; Qadir N; Suri A; Santamauro JT; Stover D
    Chest; 2013 Mar; 143(3):858-861. PubMed ID: 23460165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia.
    Pathak V; Kuhn JM; Durham C; Funkhouser WK; Henke DC
    Ann Am Thorac Soc; 2014 Jan; 11(1):87-91. PubMed ID: 24460438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case of bronchiolitis obliterans organizing pneumonia in an HIV-infected Korean patient successfully treated with clarithromycin.
    Jung IY; Jeon YD; Ahn MY; Goag E; Lee E; Ahn HW; Ahn JY; Ku NS; Kim JM; Choi JY
    BMC Infect Dis; 2015 Jul; 15():280. PubMed ID: 26201392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Febrile neutropenia in a metastatic melanoma patient treated with ipilimumab - case report.
    Woźniak S; Mackiewicz-Wysocka M; Krokowicz Ł; Kwinta Ł; Mackiewicz J
    Oncol Res Treat; 2015; 38(3):105-8. PubMed ID: 25792081
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiographic Profiling of Immune-Related Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab.
    Tirumani SH; Ramaiya NH; Keraliya A; Bailey ND; Ott PA; Hodi FS; Nishino M
    Cancer Immunol Res; 2015 Oct; 3(10):1185-92. PubMed ID: 26100356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.
    Weber J
    Oncologist; 2007 Jul; 12(7):864-72. PubMed ID: 17673617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ipilimumab-induced Ocular and Orbital Inflammation--A Case Series and Review of the Literature.
    Papavasileiou E; Prasad S; Freitag SK; Sobrin L; Lobo AM
    Ocul Immunol Inflamm; 2016; 24(2):140-6. PubMed ID: 25760920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma.
    Weber JS; Dummer R; de Pril V; Lebbé C; Hodi FS;
    Cancer; 2013 May; 119(9):1675-82. PubMed ID: 23400564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurological immune-related adverse events of ipilimumab.
    Bot I; Blank CU; Boogerd W; Brandsma D
    Pract Neurol; 2013 Aug; 13(4):278-80. PubMed ID: 23487828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of immune-related adverse events and kinetics of response with ipilimumab.
    Weber JS; Kähler KC; Hauschild A
    J Clin Oncol; 2012 Jul; 30(21):2691-7. PubMed ID: 22614989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab: a novel immunostimulatory monoclonal antibody for the treatment of cancer.
    Graziani G; Tentori L; Navarra P
    Pharmacol Res; 2012 Jan; 65(1):9-22. PubMed ID: 21930211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.
    Bhatia S; Huber BR; Upton MP; Thompson JA
    J Immunother; 2009; 32(2):203-5. PubMed ID: 19238020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchiolitis obliterans with organizing pneumonia after rituximab therapy for non-Hodgkin's lymphoma.
    Biehn SE; Kirk D; Rivera MP; Martinez AE; Khandani AH; Orlowski RZ
    Hematol Oncol; 2006 Dec; 24(4):234-7. PubMed ID: 16948177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrolides: a treatment alternative for bronchiolitis obliterans organizing pneumonia?
    Stover DE; Mangino D
    Chest; 2005 Nov; 128(5):3611-7. PubMed ID: 16304320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ipilimumab-induced toxicities and the gastroenterologist.
    Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
    J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
    Sheik Ali S; Goddard AL; Luke JJ; Donahue H; Todd DJ; Werchniak A; Vleugels RA
    JAMA Dermatol; 2015 Feb; 151(2):195-9. PubMed ID: 25321335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab-induced acute severe colitis treated by infliximab.
    Pagès C; Gornet JM; Monsel G; Allez M; Bertheau P; Bagot M; Lebbé C; Viguier M
    Melanoma Res; 2013 Jun; 23(3):227-30. PubMed ID: 23458760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events.
    Shahabi V; Berman D; Chasalow SD; Wang L; Tsuchihashi Z; Hu B; Panting L; Jure-Kunkel M; Ji RR
    J Transl Med; 2013 Mar; 11():75. PubMed ID: 23521917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.